Lyra Therapeutics (LYRA) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$22.1 million.
- Lyra Therapeutics' Enterprise Value rose 5878.25% to -$22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.1 million, marking a year-over-year increase of 5878.25%. This contributed to the annual value of -$40.6 million for FY2024, which is 6103.8% up from last year.
- Per Lyra Therapeutics' latest filing, its Enterprise Value stood at -$22.1 million for Q3 2025, which was up 5878.25% from -$29.8 million recorded in Q2 2025.
- Lyra Therapeutics' Enterprise Value's 5-year high stood at -$22.1 million during Q3 2025, with a 5-year trough of -$122.4 million in Q2 2022.
- In the last 5 years, Lyra Therapeutics' Enterprise Value had a median value of -$69.0 million in 2021 and averaged -$71.2 million.
- Per our database at Business Quant, Lyra Therapeutics' Enterprise Value plummeted by 14677.56% in 2023 and then soared by 6438.67% in 2025.
- Quarter analysis of 5 years shows Lyra Therapeutics' Enterprise Value stood at -$46.1 million in 2021, then plummeted by 115.48% to -$99.3 million in 2022, then dropped by 4.89% to -$104.1 million in 2023, then surged by 61.04% to -$40.6 million in 2024, then soared by 45.54% to -$22.1 million in 2025.
- Its last three reported values are -$22.1 million in Q3 2025, -$29.8 million for Q2 2025, and -$31.7 million during Q1 2025.